In contrast, lymphoma subtypes with activated BCR signaling are sensitive to BTK inhibitors (BTKis), and include chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and activated B cell (ABC) DLBCL. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.